Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vespula pensylvanica venom protein
- Development stage
- Unknown
- Lead developer
- ALK Abelló
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intradermal
01
Overview
Vespula pensylvanica venom protein is a sterile allergen extract derived from the Western Yellowjacket, used for both the diagnosis and treatment of Hymenoptera venom hypersensitivity. In diagnostic applications, it is utilized in skin prick or intradermal testing to identify IgE-mediated sensitivity. For therapeutic use, it is administered via venom immunotherapy (VIT), a process involving the subcutaneous injection of gradually increasing doses of the venom. This treatment induces immunological tolerance by shifting the immune response from a Th2-mediated allergic profile to a Th1 or regulatory T-cell (Treg) profile, characterized by the production of allergen-specific IgG4 blocking antibodies and increased levels of IL-10. These changes effectively inhibit the IgE-mediated release of inflammatory mediators from mast cells and basophils upon subsequent stings, significantly reducing the risk of systemic anaphylaxis.
- Brand names
- AlbayPharmalgenAquagenVenomil
- Other names
- Western Yellowjacket VenomYellow Jacket Venom Protein
02
Targets
BCR (Immunoglobulin G B Cell Receptor)High-affinity immunoglobulin epsilon receptor-bound Immunoglobulin E complexA. annua-specific IgE (Artemisia annua-specific immunoglobulin E)
Beyond the preview
Go deeper on vespula pensylvanica venom protein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vespula pensylvanica venom protein.